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Abstract
GATA-1low/low mice have an increase in megakaryocytes (MKs) and trabecular bone. The latter is 
thought to result from MKs directly stimulating osteoblastic bone formation while simultaneously 
inhibiting osteoclastogenesis. Osteoprotegerin (OPG) is known to inhibit osteoclastogenesis and 
OPG−/− mice have reduced trabecular and cortical bone due to increased osteoclastogenesis. 
Interestingly, GATA-1low/low mice have increased OPG levels. Here we sought to determine 
whether GATA-1 knockdown in OPG−/− mice could rescue the observed osteoporotic bone 
phenotype. GATA-1low/low mice were bred with OPG−/− mice and bone phenotype assessed. 
GATA-1low/low X OPG−/− mice have increased cortical bone porosity, similar to OPG−/− mice. 
Both OPG−/− and GATA-1low/low X OPG−/− mice, were found to have increased osteoclasts 
localized to cortical bone, possibly producing the observed elevated porosity. Biomechanical 
assessment indicates that OPG−/− and GATA-1low/low X OPG−/− femurs are weaker and less stiff 
than C57BL/6 or GATA-1low/low femurs. Notably, GATA-1low/low X OPG−/− mice had trabecular 
bone parameters that were not different from C57BL/6 values, suggesting that GATA-1 deficiency 
can partially rescue the trabecular bone loss observed with OPG deficiency. The fact that GATA-1 
deficiency appears to be able to partially rescue the trabecular, but not the cortical bone phenotype 
suggests that MKs can locally enhance trabecular bone volume, but that MK secreted factors 
cannot access cortical bone sufficiently to inhibit osteoclastogenesis or that OPG itself is required 
to inhibit osteoclastogenesis in cortical bone.
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Introduction
A growing body of evidence suggests that MKs and/or their growth factors play a role in 
regulating skeletal homeostasis. Our group and others have previously demonstrated that 
mice with increased numbers of MKs lead to amplified osteoblast (OB) proliferation and a 
high bone mass phenotype (Kacena, et al., 2004, Kacena, et al., 2005, Miao, et al., 2004).
Various mouse models have been described in which MK numbers are significantly 
increased and a high bone mass phenotype is observed. Mice deficient in GATA-1 or NF-
E2, transcription factors necessary for normal MK differentiation, exhibit a striking increase 
in immature abnormal MKs as well as a 3-fold increase in trabecular bone mineral density 
(Kacena, et al., 2004, Shivdasani, et al., 1995, Shivdasani, et al., 1997a). Mice 
overexpressing thrombopoietin (TPO), the major MK growth factor, exhibit a four-fold 
increase of MKs and an osteosclerotic bone phenotype (Villeval, et al., 1997, Yan, et al., 
1996). A mouse model of platelet-type von Willebrand disease has also been shown to yield 
increased numbers of MKs and a high bone mass phenotype (Suva, et al., 2008). Taken 
together, these findings suggest a role for MKs in regulation of bone mass.
Importantly, MKs can influence regulation of bone mass by secretion of various bone matrix 
proteins and growth factors important in bone remodeling (Thiede, et al., 1994, Kelm, et al., 
1992, Breton-Gorius, et al., 1992, Sipe, et al., 2004, Vannucchi, et al., 2002, Wickenhauser, 
et al., 1995). In vitro, MKs regulate osteoblastogenesis via a direct cell-to-cell contact 
mechanism, showing a 3–6 fold increase in OB proliferation (Kacena, et al., 2004, Miao, et 
al., 2004). In addition to altering OB proliferation, MKs have the ability to regulate 
osteoclastogenesis both directly and indirectly. In vitro, osteoclast (OC) formation is 
inhibited up to 10-fold by MKs or MK conditioned medium. The MK conditioned medium 
contained OPG, although at levels well below those used to inhibit OC development, 
suggesting a yet unknown soluble factor is responsible for the OC inhibitory effect (Kacena, 
et al., 2006, Beeton, et al., 2006). In addition to this direct inhibitory effect, MKs can also 
indirectly inhibit OC development by increasing expression of OPG in OBs (Bord, et al., 
2005, Kacena, et al., 2006).
OPG acts as a decoy receptor for RANKL by blocking its interaction with RANK, therefore 
inhibiting OC development. OPG−/− mice have a striking increase in OC number and a 
concomitant osteoporotic bone phenotype (Simonet, et al., 1997). Here we show that 
introducing a GATA-1 deficiency into OPG−/− mice can rescue the low trabecular bone 
mass phenotype observed in OPG deficiency but not the low cortical bone mass phenotype.
Materials and Methods
Mice
For these studies 5 month-old female GATA-1low/low, C57BL/6, OPG−/−, and 
GATA-1low/low X OPG−/− mice were utilized. OPG−/− mice were kindly provided by 
Amgen. Generation and breeding of mutant mice with selective loss of MK-expressed 
GATA-1 were described previously (Villeval, et al., 1997, McDevitt, et al., 1997, 
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Shivdasani, et al., 1997b). In brief, a DNAse 1-hypersensitive region (HS) was identified 
upstream of the GATA-1 promoter and was subsequently knocked out by insertion of a 
neomycin-resistant cassette. This resulted in mice with reduced levels of GATA-1 mRNA 
and protein (3–5 fold reduction in protein), a functional knockdown. These mice have been 
backcrossed more than 11 generations have been maintained on the C57BL/6 background, 
and were kindly provided by Dr. Stuart Orkin. GATA-1low/low and OPG−/− mice were 
crossed to produce GATA-1low/low X OPG−/− mice. C57BL/6 mice were obtained from 
Jackson Laboratories. All procedures were approved by the Institutional Animal Care and 
Use Committee (IACUC) of the Indiana University School of Medicine and followed NIH 
guidelines.
Serum OPG Measurements
Whole blood from C57BL/6 and GATA-1low/low mice was collected at euthanasia, serum 
separated, and serum concentration of total OPG was determined by using the mouse OPG 
Quantikine ELISA kit from R&D Systems according to the manufacturer’s 
recommendations.
Preparation of Neonatal Calvarial Cells (OB)
Neonatal murine calvarial OB cells were prepared as previously described (Horowitz, et al., 
1994) from C57BL/6, GATA-1low/low, OPG−/−, and GATA-1low/low X OPG−/− mice. Our 
technique was a modification of the basic method described by Wong (Wong and Cohn, 
1975). Briefly, calvaria were dissected from neonatal mice and then treated with EDTA in 
PBS for 30 min. Calvaria were then subjected to sequential collagenase digestions (200U/
mL). Fractions 3–5 (digestions incubated at 37°C for 20–35, 35–50, and 50–65 min, 
respectively) were collected and used as the OB starting population. These cells were ~90% 
OB or OB precursors based on previously reported established criteria (Horowitz, et al., 
1994, Simmons, et al., 1982, Jilka and Cohn, 1981). OBs were seeded at 2×104 cells/ml 
(optimal pre-tested). OB in culture were maintained in αMEM supplemented with 10% fetal 
bovine serum and were further supplemented with ascorbic acid (50 mg/ml added on day 0 
and day 3). β-glycerophosphate (5mM) is normally added starting on day 7 and all 
subsequent feedings, but for these studies cells were collected at day 7 prior to feeding.
Preparation of Fetal Liver Derived MKs
Murine MKs were prepared as previously described (Kacena, et al., 2004, Kacena, et al., 
2006). In short, fetuses were dissected from pregnant WT C57BL/6, GATA-1low/low, 
OPG−/−, and GATA-1low/low X OPG−/− mice at E13–15. The livers were removed and 
single cell suspensions were made, washed, and seeded in 100 ml culture dishes, in 
Dulbecco modified eagle medium (DMEM) supplemented with 10% FCS and 1% murine 
TPO (Villeval, et al., 1997). After ~5 days, MKs were obtained by separating them from the 
lymphocytes and other cells using a one-step albumin gradient to obtain a 90–95% pure MK 
population (Drachman, et al., 1997).
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Histomorphometry
The C57BL/6, GATA-1low/low, OPG−/−, and GATA-1low/low X OPG−/− mice were 
administered an intraperitioneal injection of the fluorochrome calcein (30mg/kg) 13 and 3 
days prior to sacrifice to label actively forming bone surfaces. At sacrifice the right femur 
was removed and stored in 10% neutral buffered formalin (NBF) for 48 hours, and then 
transferred to 70% ethanol (EtOH) for storage prior to processing. Static and dynamic 
histomorphometric analysis of trabecular bone was completed on the distal femur as 
previously described (Feher, et al., 2010, Warden, et al., 2008). Tartrate resistant acid 
phosphatase staining was used to identify osteoclasts in the distal femur as detailed 
previously (Feher, et al., 2010, Warden, et al., 2008). Histological measurements were made 
with a semiautomatic analysis system (Bioquant OSTEO 7.20.10, Bioquant Image Analysis 
Co.) attached to a microscope with an ultraviolet light source (Nikon Optiphot 2 microscope, 
Nikon). Measurements were done on one von Kossa/McNeal’s stained (static) and one 
unstained (dynamic) section for each animal. All analyses were performed blinded to 
treatment group.
Micro-Computed Tomography (μCT)
A desktop micro-computed tomography machine (μCT, Skyscan 1172) was used to acquire 
images of cortical and trabecular bone parameters of the right femur as previously detailed 
(Feher, et al., 2010, Warden, et al., 2008, Weatherholt, et al., 2013). μCT scanning was 
performed on the femur sequestered for histology. In brief, images were acquired at an 
isotropic voxel size of 60 μm, with an energy level of 60kV, and an aluminum 0.5 mm filter. 
After images were acquired, data was reconstructed using NRecon reconstruction software 
(skyscan), and then converted to three-dimensional images. For the trabecular bone 
properties, a 1-mm-thick region of interest was analyzed beginning 0.5 mm distal to the 
growth plate. The following parameters were derived from the distal femur: trabecular bone 
volume fraction (BV/TV, %), trabecular number (Tb.N, 1/mm), trabecular thickness (Tb.Th, 
mm), and trabecular separation (Tb.Sp, mm). For cortical bone properties, a 0.5-mm tick 
region of interest of the femoral mid-shaft was used to calculate polar moment of inertia (Ip, 
mm4)
Biomechanics
Relative bone strength was determined by performing three-point bending of the left femur 
with a materials testing device (MTS Systems Corporation; Eden Prairie, MN) as previously 
detailed (Warden, et al., 2008, Feher, et al., 2010, Weatherholt, et al., 2013). In brief, at 
sacrifice the removed femur was wrapped in a saline-soaked guaze and stored at −20°C until 
evaluation. Femurs were then thawed to room temperature in a saline bath for two hours, 
completed μCT as detailed above, and then immediately each femur was tested in the 
anterior-posterior direction with a span width of 10 mm and stabilized with a static preload 
of 1 N before being loaded to failure in three-point bending with a crosshead speed of 10 
mm/min. Force versus displacement data was gathered at 100 Hz, and the ultimate force (N), 
stiffness (N/mm), polar moment of inertia, ultimate stress (MPa), modulus (MPa), and 
toughness (MJ/m3) were obtained/derived.
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Quantitative Real-Time PCR
Total RNA was isolated using Trizol Reagent as directed by the manufacturer (Invitrogen 
Corporation). 1ug of RNA isolated using Trizol Reagent was used to generate cDNA by 
reverse transcription according to the manufacturer’s instructions (First Strand cDNA 
Synthesis Kit for RT-PCR; Roche Applied Science). Quantitative Real-Time PCR (qRT-
PCR) reactions were performed in an ABI Prism 7900HT sequence detection system 
(Applied Biosystems) using Power SYBR Green PCR Master Mix reagent following the 
manufacturer’s instructions for relative quantification (Applied Biosystems).
For each gene analyzed, a calibration curve was performed and all the oligonucleotides were 
tested to ensure specificity and sensitivity. For each sample, relative mRNA expression of 
the target genes were derived using the 2−ΔΔCT calculation. GAPDH was used as an internal 
control. For each target gene, the corresponding WT sample was used as the calibrator for 
relative expression. Primer pair sequences used are:
GATA-1 forward primer: 5′ CAGCATCTTCTTCCACTTCC
GATA-1 reverse primer: 5′ AGGCATAAGATGGCTGACAG
OPG forward primer: 5′ CCGAGTGTGTGAGTGTGAGG
OPG reverse primer: 5′ CCAGCTTGCACCACTCCAA
GAPDH forward primer: 5′ CGTGGGGCTGCCCAGAACAT
GAPDH reverse primer: 5′ TCTCCAGGCGGCACGTCAGA
Statistics
Unless otherwise stated, all data are presented as the Mean ± 1 SD. All cell experiments 
were performed at least three times with duplicate or triplicate samples in each experiment. 
For in vivo studies, the sample size is presented in the corresponding figure legends. 
Student’s t-test were performed when only two groups were compared. As male and female 
mouse bones exhibited virtually identical properties, for ease of reporting and to increase the 
sample size, data from male and female mice were combined for all of the in vivo data 
analysis. One-way factorial analyses of variances with LSD were used to make multiple 
group comparisons. All analyses were performed with the Statistical Package for Social 
Sciences (IBM SPSS 19; SPSS Inc., Armonk, NY) software and were two tailed with a level 
of significance set at 0.05.
Results
Generation and Validation of Mice deficient in OPG and GATA-1
GATA-1low/low and OPG−/− mice, both on C57BL/6 background, were crossed to generate 
mice with GATA-1low/low X OPG−/−. Generation was performed by crossing over 11 
generations. Genotyping was used to confirm GATA-1low/low X OPG−/− mice. These mice 
exhibited normal body weight, litter size, fertility, and normal mendellian distribution 
compared to controls (data not shown). RT-PCR of isolated OBs and MKs confirms 
GATA-1 and OPG mRNA expression levels, summarized in Figure 1. Specifically, as 
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GATA-1 is expressed in MK lineage cells but not OB lineage cells (Kacena, et al., 2004), 
we examined GATA-1 expression in MKs generated from the 4 types of mice. As would be 
expected, GATA-1low/low and GATA-1low/low X OPG−/− mice had low levels of GATA-1 
expression compared to the levels of GATA-1 observed in C57BL/6 and OPG−/− mice. On 
the other hand, OB lineage cells are known to express OPG, therefore we examined OPG 
expression in OBs generated from the 4 types of mice. As expected, OPG was not detected 
with 35 cycles in OBs derived from mice lacking OPG (OPG−/− and GATA-1low/low X 
OPG−/− mice).
Trabecular Bone Properties in GATA-1 low/low X OPG−/− and Control Mice
As OPG−/− mice have a low trabecular bone phenotype (Simonet, et al., 1997) and 
GATA-1low/low mice have an increased trabecular bone phenotype (Kacena, et al., 2004, 
Kacena, et al., 2013), we hypothesized that GATA-1 deficiency may be able to rescue the 
low trabecular bone mass phenotype observed in OPG−/− mice. This hypothesis was further 
supported by data shown in Figure 2, whereby serum OPG levels are markedly elevated in 
GATA-1low/low mice (2908pg/ml±322pg/ml) compared to their littermate C57BL/6 control 
mice (2048pg/ml±208pg/ml). Therefore, to test this possibility we used microCT and 
histomorphopemtric analyses and examined the femurs from all 4 groups of mice, Table 1 
summarizes the findings.
First, we confirmed our previous reports (Kacena, et al., 2004, Kacena, et al., 2013) and 
demonstrated using microCT the distal femur of GATA-1low/low mice to have significantly 
more bone volume (BV/TV: 10.5%±2.6%), increased bone surfaces (BS/TV: 7.9/mm±1.8/
mm), and increased numbers of trabeculae (Tb.N: 2.06/mm±0.50/mm) compared to 
C57BL/6 mice (BV/TV: 3.9%±0.3%, BS/TV: 3.8/mm±0.2/mm, and Tb.N: 0.81/mm
±0.04/mm, respectively). Consistent with the microCT findings, histomorphometric analyses 
also confirmed our previous reports (Kacena, et al., 2004, Kacena, et al., 2013) that bone 
volume (BV/TV: 14.1%±2.7%) was significantly elevated in the distal femurs of 
GATA-1low/low mice due to a high bone turnover state with a significant 2.6 fold increase in 
number of OBs (N.Ob/T.Ar: 86±11) and a 2.2 fold increase in number of OCs (N.Oc/T.Ar: 
53±5) compared to that measured in C57BL/6 mice (BV/TV: 3.6%±0.3%, N.Ob/T.Ar: 
33±4, and N.Oc/T.Ar: 24±2, respectively). Figure 3, depicts representative TRAP stained 
histological sections of the distal femur for all groups of mice.
Second, we confirmed previous reports regarding the low bone mass phenotype observed in 
OPG−/− mice (Simonet, et al., 1997). With respect to microCT analyses, as shown in Table 
1, the distal femur of OPG−/− mice have significantly reduced bone volume (BV/TV: 0.4%
±0.2%), bone surfaces (BS/TV: 2.1/mm±0.3/mm), and trabeculae number (Tb.N: 0.13/mm
±0.06/mm) than do C57BL/6 mice (3.9%±0.3%, 3.8/mm±0.2/mm, and 0.81/mm±0.04/mm, 
respectively). With regard to histomorphometric analyses, as displayed in Table 1, and 
shown in Figure 3, OPG−/− femurs have significantly reduced bone volume (BV/TV: 0.8%
±0.4%) with reduced numbers of both OBs (8±4) and OCs (8±4) compared to C57BL/6 
mice (3.6%±0.3%, 33±4, and 24±2, respectively).
Next, we examined the contribution of GATA-1 knockdown in OPG−/− mice 
(GATA-1low/low X OPG−/−) on trabecular bone phenotype. The data are summarized in 
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Table 1. As assessed by microCT, although GATA-1low/low mice had significantly elevated 
bone volume (BV/TV: 10.5%±2.6%), increased bone surfaces (BS/TV: 7.9/mm±1.8/mm), 
and increased numbers of trabeculae (Tb.N: 2.06/mm±0.50/mm) compared to 
GATA-1low/low X OPG−/− (BV/TV: 2.9%±1.0%, BS/TV: 2.5/mm±0.8/mm, and Tb.N: 
0.58/mm±0.19/mm, respectively), OPG−/− (BV/TV:0.4%±0.2%, BS/TV: 2.1/mm±0.3/mm, 
and Tb.N: 0.13/mm±0.06/mm, respectively), and C57BL/6 (BV/TV:3.9%±0.3%, BS/TV: 
3.8/mm±0.2/mm, and Tb.N: 0.81/mm±0.04/mm, respectively) mice; significant differences 
in bone volume, bone surface, and trabecular number were not found between 
GATA-1low/low X OPG−/− and OPG−/− or C57BL/6 mice.
However, the values observed in GATA-1low/low X OPG−/− femurs were closer in value to 
that observed in C57BL/6 mice as compared to OPG−/− femurs, suggesting a partial rescue 
of the trabecular phenotype. Indeed, significant differences were observed between 
C57BL/6 and OPG−/− femurs, whereas GATA-1low/low X OPG−/− femurs were not 
statistically different from C57BL/6 mice. Similar trends were observed when femurs were 
examined histomorphometrically, including that changes in OB and OC numbers. 
Interestingly, both OB and OC numbers while dramatically reduced 2–3 fold with OPG 
deficiency (OPG−/− and GATA-1low/low X OPG−/− mice) compared to C57BL/6 mice, 
GATA-1low/low X OPG−/− mice had 50% more OBs and OCs than did OPG−/− mice, again 
suggesting a partial rescue in trabecular bone phenotype. Of interest, TRAP staining (see 
Figure 3) demonstrated that numerous OCs were localized to the cortical bone, which was 
not observed in C57BL/6 or GATA-1low/low mice. This latter observations suggests 
difference is cortical bone properties.
Cortical Bone Properties in GATA-1 low/low X OPG−/− and Control Mice
Cortical bone properties derived histologically were examined and are detailed in Table 2. 
GATA-1low/low X OPG−/− mice have a significantly larger cross sectional area 
(2.15μm2±0.11μm2) compared to GATA-1low/low (1.46μm2±0.05μm2), OPG−/− 
(1.56μm2±0.16μm2), and C57BL/6 control (1.64μm2±0.01μm2) mice. OPG−/− mice have a 
significantly lower bone area (0.57μm2±0.04μm2) compared to GATA-1low/low 
(0.85μm2±0.35μm2) and C57BL/6 mice (0.76μm2±0.07μm2). Bone area was significantly 
elevated (0.80μm2±0.03μm2) in GATA-1low/low X OPG−/− mice compared to OPG−/− mice, 
and comparable to C57BL/6 and GATA-1low/low mice. Porosity was increased significantly 
in OPG−/− mice (8.24%±1.61%) compared to GATA-1low/low (0.23%±0.09%) and C57BL6 
mice (0.13%±0.03%). Additionally, the cortical porosity in GATA-1low/low X OPG−/− mice 
(14.80%±1.73%) was significantly elevated (1.8-fold higher) compared to that observed in 
the OPG−/− mice (8.24%±1.61%), and was also significantly higher than that measured in 
both the GATA-1low/low and C57BL/6 mice. These results are illustrated by the microCT 
images of each respective genotype shown in Figure 4. Increased porosity in GATA-1low/low 
X OPG−/− cortical bone is also evident in calcein labeled sections, shown in Figure 5. As 
alterations in cortical bone were observed, it is likely that biomechanical and/or biomaterial 
properties would also be altered.
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Biomechanical and Biomaterial Properties in GATA-1 low/low X OPG−/− and Control Mice
Table 3 summarizes the bone biomechanical and material properties in GATA-1low/low X 
OPG−/−, OPG−/−, GATA-1low/low and C57BL/6 femurs. Of all of the properties measured, 
only the polar moment of inertia was significantly different between GATA-1low/low X 
OPG−/− and OPG−/− femurs (elevated in GATA-1low/low X OPG−/−mice). This is consistent 
with the increase in cross sectional area observed in GATA-1low/low X OPG−/− mice (Table 
2). However, GATA-1low/low X OPG−/− and OPG−/− femurs exhibited significant reductions 
in stiffness, ultimate failure, load at peak, modulus, and energy to ultimate failure compared 
to C57BL/6 and GATA-1low/low femurs. Specifically, GATA-1low/low X OPG−/− femurs 
showed a significant decrease in stiffness (41.1N/mm±3.7N/mm) compared to C57BL/6 
(129.7N/mm±3.6N/mm) and GATA-1low/low (135.3N/mm±6.7N/mm) femurs. Additionally, 
GATA-1low/low X OPG−/− femurs showed a decreased load at peak (6.6N±1.1N) compared 
to C57BL/6 (22.5N±0.1N) and GATA-1low/low (25.7N±0.7N) femurs. Assessment of 
biomechanical properties indicates that OPG−/− and GATA-1low/low X OPG−/− femurs are 
weaker and less stiff, as demonstrated by low stiffness, ultimate failure, and load at peak, 
compared to the corresponding biomechanical properties of C57BL/6 or GATA-1low/low 
femurs.
Discussion
GATA-1low/low mice exhibit a striking increase in trabecular bone and increased levels of 
immature abnormal MKs (Kacena, et al., 2004, Shivdasani, et al., 1995, Shivdasani, et al., 
1997a). MKs have been shown to stimulate OB proliferation via a direct cell-to-cell contact 
mechanism (Kacena, et al., 2004, Kacena, et al., 2005, Miao, et al., 2004) and are also able 
to stimulate OBs to increase secretion of OPG to inhibit OCs (Bord, et al., 2005, Kacena, et 
al., 2006). Additionally, MKs and MK conditioned media have been shown to decrease OC 
formation by up to 10-fold due to a yet unidentified secreted inhibitory molecule. OPG−/− 
mice exhibit a drastic increase in number of OCs, which leads to a severe osteoporotic bone 
phenotype (Kacena, et al., 2006, Beeton, et al., 2006). A GATA-1 knockdown was crossed 
into OPG−/− mice (GATA-1low/low X OPG−/−) to determine whether the osteoporotic bone 
phenotype observed in OPG−/− mice could be reversed through a MK-mediated mechanism.
As detailed in Table 2 and shown in Figures 4 and 5, GATA-1low/low X OPG−/− mouse 
cortical bone resembled that seen in OPG−/− mice. The increased porosity observed in OPG 
deficient mice remained in mice deficient in both OPG and GATA-1. Although the cortical 
bone phenotype was not rescued in GATA-1low/low X OPG−/− mice, changes in trabecular 
bone properties were observed in femurs of mice deficient in both OPG and GATA-1. 
GATA-1low/low X OPG−/− femurs showed significant increases in trabecular thickness along 
with an expected decrease in trabecular separation, detailed in Table 2. GATA-1low/low mice 
have significantly greater trabecular bone volume than C57BL/6, OPG−/−, and 
GATA-1low/low x OPG−/− mice. C57BL/6 and GATA-1low/low x OPG−/− mice have similar 
amounts of trabecular bone volume, with OPG−/− mice having the least amount of trabecular 
bone volume. These results indicate a partial rescue of trabecular, but not cortical bone in 
mice deficient in both OPG and GATA-1.
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Interestingly, mice deficient in OPG (OPG−/− and GATA-1low/low X OPG−/−) were found to 
have OCs localized to the cortical bone of femurs. OCs were not found in cortical bone of 
GATA-1low/low or C57BL/6 femurs (Figure 2). Increased cortical porosity observed through 
histomorphometric analyses in mice lacking OPG is likely due to the increased number of 
OCs in cortical bone.
With regard to biomechanical properties, detailed in Table 3, femurs from GATA-1low/low X 
OPG−/− were weaker and less stiff compared to C57BL/6 mice despite having an increase in 
bone size. Given that cortical bone is a primary contributor to biomechanical bone properties 
and as GATA-1 deficiency was unable to resolve the increase in porosity observed in 
GATA-1low/low X OPG−/− mice, it was expected that the femurs of GATA-1low/low x 
OPG−/− and OPG−/− would not be as stiff nor strong as those measured in C57BL/6 and 
GATA-1low/low mice.
In conclusion, we have shown that GATA-1 deficiency is able to partially rescue trabecular 
bone but not cortical bone in OPG−/− mice. While it remains unclear as to why trabecular 
bone is partially rescued while cortical bone is not, we speculate that MKs have more 
opportunity for direct interactions in trabecular bone. Additionally, MK secreted factors may 
not be able to efficiently produce the expected inhibition of osteoclasts in cortical bone due 
to physical barrier. Alternatively, as GATA-1low/low mice have increased levels of OPG, it is 
possible that the rescue of the cortical phenotype is dependent on OPG. More work remains 
to understand how megakaryocyte-mediated interactions regulate the repair of trabecular 
and cortical bone.
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Figure 1. 
mRNA expression in C57BL/6, GATA-1low/low, OPG−/−, and GATAlow/low X OPG−/− MKs 
(A) and OBs (B). MKs were obtained by separating them from other cells after culturing for 
5 days with TPO stimulation. OBs were cultured under osteogenic conditions as detailed 
above for 7 days. Real-time PCR was used to determine mRNA expression of GATA-1 and 
OPG, respectively. GAPDH was used to normalize the amount of the investigated transcript. 
Expression levels for both GATA-1 in MKs and and OPG in OBs confirms mouse 
genotyping.
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Figure 2. 
OPG serum concentration was measured in 5-month-old, GATA-1low/low and littermate, 
C57BL/6 control mice. OPG levels are significantly increased in GATA-1low/low mice 
compared to WT littermate controls (n=5/group,*p=0.001).
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Figure 3. 
Tartrate resistant acid phosphatase (TRAP) staining of longitudinal sections taken from the 
distal femur of 5 month-old, female C57BL/6 (A), GATA-1low/low (B), OPG−/− (C) and 
GATAlow/low X OPG−/− (D) mice. Examination of the cortical bone from these mice shows 
that numerous OCs are present in the cortical bone of OPG−/− and GATA-low/low X OPG−/− 
mice. No OCs were observed in the cortical bone of C57BL/6 (A) or GATA-1low/low mice. 
Original magnification, 20X.
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Figure 4. 
MicroCT imaging of 5 month-old, female C57BL/6 (A), GATA-1low/low (B), OPG−/− (C), 
and GATA-1low/low X OPG−/− (D) mice. These images illustrate increased porosity 
observed in OPG deficient mice, which remained in mice deficient in both GATA-1 and 
OPG.
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Figure 5. 
5 month-old, female C57BL/6 (A), GATA-1low/low (B), OPG−/− (C), and GATA-1low/low X 
OPG−/− (D) mice were injected with the fluorochrome calcein 13 and 3 days prior to 
euthanasia to calculate dynamic histological indicies of bone formation. Cross-sections were 
obtained at the femur midshaft. These images depict increased bone formation on the 
endocortical surface in GATA-1low/low (B), OPG−/− (C), and GATA-1low/low X OPG−/− (D) 
mice as compared to C57BL/6 control mice (A). The increased cortical porosity in OPG−/− 
and GATA-1low/low X OPG−/− is also clearly evident by the excessive amount of calcein 
found through the cortical bone. Original magnification, 5X.
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